Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of IGSC 20% in Primary Immunodeficiency
NCT02604810Phase 3Completed
- Sponsor
- Grifols
- Start
- Jan 2016
- Primary completion
- Sep 2017
- Modality
- Biologic
- Countries
- 2
01
Overview
A Phase 3 trial of immune globulin subcutaneous, human-klhw in primary immunodeficiency (PI), sponsored by Grifols. Started Jan 2016; status: completed.
02
Drugs
immune globulin subcutaneous, human-klhw
03
Conditions
primary immunodeficiency (PI)
Beyond the preview
Go deeper on NCT02604810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02604810.